Masui N, Kumano K, Mashimo S, Endo T
Department of Urology, Kitasato University School of Medicine.
Nihon Hinyokika Gakkai Zasshi. 1994 Nov;85(11):1622-8. doi: 10.5980/jpnjurol1989.85.1622.
Endothelin (ET) has been suggested to be involved in acute graft rejection of kidney transplantation and cyclosporin A (CsA) nephrotoxicity. For clarification of the pathophysiological role of ET in the early post-transplantation period, plasma endothelin-1 (ET-1) was measured by specific radioimmunoassay in renal transplant recipients, patients on maintenance hemodialysis (HD) and healthy volunteers. Twelve transplant recipients were used in this study, 8 of whom were living related subjects and 4 cadaver. Plasma ET-1 and graft function were measured each day, from 1 day prior and 7 days following transplantation and every week up to 5 weeks postoperatively. Plasma ET was measured in 20 other transplant recipients with stable function (serum creatinine < or = 1.8 mg/dl), 20 maintenance HD patients with no residual renal function and 6 healthy volunteers. Mean plasma ET-1 was 13.0 +/- 4.5 pg/ml in 20 recipients with stable graft function, 21.7 +/- 6.5 in 20 HD patients and 1.5 +/- 0.4 in healthy volunteers. These differences are statistically significant (p < 0.02). Plasma ET-1 showed significant decrease from 21.8 +/- 7.2 pg/ml prior to transplantation to 12.8 +/- 4.0 when urinary output reached more than 1000 ml in living and cadaveric transplantation subjects. All three acute vascular rejections clearly indicated histologically increased plasma ET-1 accompanied by an increase in serum creatinine. A significant positive liner correlation was noted between plasma ET-1 and serum creatinine during the first week following living transplantation. Two patients with clinically and histologically suspected CsA nephrotoxicity showed transient increase in plasma ET-1.(ABSTRACT TRUNCATED AT 250 WORDS)
内皮素(ET)被认为与肾移植的急性移植物排斥反应及环孢素A(CsA)肾毒性有关。为阐明ET在移植后早期的病理生理作用,采用特异性放射免疫分析法对肾移植受者、维持性血液透析(HD)患者及健康志愿者的血浆内皮素-1(ET-1)进行了检测。本研究共纳入12例移植受者,其中8例为亲属活体供肾,4例为尸体供肾。于移植前1天及移植后7天内每天测量血浆ET-1及移植物功能,术后每周测量直至5周。对另外20例移植肾功能稳定(血清肌酐≤1.8mg/dl)的受者、20例无残余肾功能的维持性HD患者及6例健康志愿者的血浆ET进行了检测。20例移植肾功能稳定的受者平均血浆ET-1为13.0±4.5pg/ml,20例HD患者为21.7±6.5pg/ml,健康志愿者为1.5±0.4pg/ml。这些差异具有统计学意义(p<0.02)。在活体及尸体供肾移植受者中,当尿量超过1000ml时,血浆ET-1从移植前的21.8±7.2pg/ml显著降至12.8±4.0pg/ml。所有3例急性血管排斥反应在组织学上均显示血浆ET-1升高,同时血清肌酐升高。活体移植后第一周,血浆ET-1与血清肌酐之间存在显著的正线性相关。2例临床及组织学怀疑有CsA肾毒性的患者血浆ET-1出现短暂升高。(摘要截短至250字)